If phase III clinical trials are successful, researchers suggest categorizing the drug as schedule IV

In an evaluation of the safety and abuse research on the drug in hallucinogenic mushrooms, researchers suggest that if it clears phase III clinical trials, psilocybin should be re-categorized from a schedule I drug — one with no known medical potential — to a schedule IV drug such as prescription sleep aids, but with tighter control.

In an evaluation of the safety and abuse research on the drug in hallucinogenic mushrooms, Johns Hopkins researchers suggest that if it clears phase III clinical trials, psilocybin should be re-categorized from a schedule I drug — one with no known medical potential — to a schedule IV drug such as prescription sleep aids, but with tighter control.

 

Read from original article